Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-07-08
2009-10-06
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S157000
Reexamination Certificate
active
07598268
ABSTRACT:
Organic compounds having the formula I are provided where the variables have the values described herein.Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.
REFERENCES:
patent: 3663606 (1972-05-01), Isowa
patent: 4659657 (1987-04-01), Harnisch et al.
patent: 4882342 (1989-11-01), Von der Saal et al.
patent: 5073492 (1991-12-01), Chen et al.
patent: 5151360 (1992-09-01), Handa et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5414088 (1995-05-01), Von Der Saal et al.
patent: 5585380 (1996-12-01), Bianco et al.
patent: 5646153 (1997-07-01), Spada et al.
patent: 5710158 (1998-01-01), Myers et al.
patent: 5763441 (1998-06-01), App et al.
patent: 5792771 (1998-08-01), App et al.
patent: 5801212 (1998-09-01), Okamoto et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: RE36256 (1999-07-01), Spada et al.
patent: 5942385 (1999-08-01), Hirth
patent: 5981569 (1999-11-01), App et al.
patent: 6057320 (2000-05-01), Spada et al.
patent: 6111110 (2000-08-01), Brennan et al.
patent: 6137010 (2000-10-01), Joo et al.
patent: 6174912 (2001-01-01), Beck et al.
patent: 6258951 (2001-07-01), Lohmann et al.
patent: 6303600 (2001-10-01), Cox et al.
patent: 6306874 (2001-10-01), Fraley et al.
patent: 6313138 (2001-11-01), Fraley et al.
patent: RE37650 (2002-04-01), Myers et al.
patent: 6420382 (2002-07-01), Fraley et al.
patent: 6479512 (2002-11-01), Fraley et al.
patent: 6593344 (2003-07-01), Biedermann et al.
patent: 6605617 (2003-08-01), Renhowe et al.
patent: 6759417 (2004-07-01), Renhowe et al.
patent: 6762194 (2004-07-01), Renhowe et al.
patent: 6774237 (2004-08-01), Renhowe et al.
patent: 6774327 (2004-08-01), Wong
patent: 6800760 (2004-10-01), Renhowe et al.
patent: 7179912 (2007-02-01), Halbrook et al.
patent: 2002/0103230 (2002-08-01), Renhowe et al.
patent: 2002/0107392 (2002-08-01), Renhowe et al.
patent: 2003/0028018 (2003-02-01), Renhowe et al.
patent: 2003/0087854 (2003-05-01), Monia et al.
patent: 2003/0207883 (2003-11-01), Renhowe et al.
patent: 2004/0002518 (2004-01-01), Renhowe et al.
patent: 2004/0092535 (2004-05-01), Barsanti et al.
patent: 2004/0097545 (2004-05-01), Renhowe et al.
patent: 2004/0220196 (2004-11-01), Hannah et al.
patent: 2005/0054672 (2005-03-01), Renhowe et al.
patent: 2005/0137399 (2005-06-01), Cai et al.
patent: 2005/0203101 (2005-09-01), Barsanti et al.
patent: 2005/0209247 (2005-09-01), Cai et al.
patent: 2005/0256157 (2005-11-01), Gesner et al.
patent: 2005/0261307 (2005-11-01), Cai et al.
patent: 2363459 (1975-06-01), None
patent: 3634066 (1986-07-01), None
patent: 19841985 (2000-03-01), None
patent: 0290153 (1988-11-01), None
patent: 0 509 717 (1992-04-01), None
patent: 0 508 800 (1992-10-01), None
patent: 0 747 771 (1996-12-01), None
patent: 0 797 376 (1997-09-01), None
patent: 0 290 153 (1998-11-01), None
patent: 1 086 705 (2001-03-01), None
patent: P0104752 (2002-07-01), None
patent: 59-130284 (1984-07-01), None
patent: 63230687 (1988-09-01), None
patent: 6-9952 (1994-01-01), None
patent: 7-43896 (1995-02-01), None
patent: 8-29973 (1996-02-01), None
patent: 63-258903 (1998-10-01), None
patent: WO 91/04974 (1991-04-01), None
patent: 92/18483 (1992-10-01), None
patent: 92/20642 (1992-11-01), None
patent: 95/15758 (1995-06-01), None
patent: 95/18801 (1995-07-01), None
patent: 97/03069 (1997-01-01), None
patent: 97/34876 (1997-09-01), None
patent: 97/48694 (1997-12-01), None
patent: 98/13350 (1998-04-01), None
patent: WO 1998/055124 (1998-12-01), None
patent: 99/10349 (1999-03-01), None
patent: 99/50263 (1999-10-01), None
patent: 99/65897 (1999-12-01), None
patent: WO 00/00481 (2000-01-01), None
patent: WO 00/03990 (2000-01-01), None
patent: WO 00/20400 (2000-04-01), None
patent: 00/27379 (2000-05-01), None
patent: WO 00/58315 (2000-10-01), None
patent: WO 00/71129 (2000-11-01), None
patent: WO 2000/74683 (2000-12-01), None
patent: 01/02369 (2001-01-01), None
patent: WO 01/12169 (2001-02-01), None
patent: 01/28993 (2001-04-01), None
patent: 01/29025 (2001-04-01), None
patent: WO 01/28993 (2001-04-01), None
patent: 01/52904 (2001-07-01), None
patent: WO 01/52875 (2001-07-01), None
patent: WO 01/53268 (2001-07-01), None
patent: 01/55114 (2001-08-01), None
patent: 01/62251 (2001-08-01), None
patent: 01/62252 (2001-08-01), None
patent: WO 01/74296 (2001-10-01), None
patent: WO 02/18383 (2002-03-01), None
patent: WO 02/22598 (2002-03-01), None
patent: 02/32861 (2002-04-01), None
patent: WO 02/26716 (2002-04-01), None
patent: WO 02/058697 (2002-08-01), None
patent: WO 03/004488 (2003-01-01), None
patent: WO 03/033472 (2003-04-01), None
patent: WO 03/087095 (2003-10-01), None
patent: WO 2004/018419 (2004-03-01), None
patent: WO 2004/030620 (2004-04-01), None
patent: WO 2004/031401 (2004-04-01), None
patent: WO 2004/043389 (2004-05-01), None
patent: WO 2004/063151 (2004-07-01), None
patent: WO 2004/063170 (2004-07-01), None
patent: WO 2004/087153 (2004-10-01), None
patent: WO 2005/046589 (2005-05-01), None
patent: WO 2005/046590 (2005-05-01), None
patent: WO 2005/053692 (2005-06-01), None
patent: WO 2005/082340 (2005-09-01), None
patent: WO 2006/081445 (2006-08-01), None
Gontero, European Urology, vol. 46, pp. 296-311, 2004.
Kirstein, CA 145:201781, abstract only of Recent Patents on Anti-cancer Drug Discovery, vol. 1(2), pp. 153-161, 2006.
Salmon, S. E. et al.,Basic&Clincial Pharmacology, Seventh Edition, edited by B. Katzung, Appleton & Lange, pp. 29, 881-884 (1998).
Milauer, B. et al., “Glioblastoma Growth Inhibited in Vivo by a Dominant-Negative Flk-1 Mutant,”Nature, vol. 367, pp. 576-579 (1994); published by Nature Publishing Group.
Pinedo, H. M. et al., “Translational Research: The Role of VEGF in Tumor Angiogenesis,”The Oncologist 2000, vol. 5 (suppl. 1), pp. 1-2 (2000).
McMahon, G., “VEGF receptor Signaling in Tumor Angiogenesis,”The Oncologist 2000, vol. 5 (suppl. 1), pp. 3-10 (2000).
European Search Report dated Feb. 28, 2006 for EP 05017665.0.
Cecil, Textbook of Medicine, 21stEdition (2000), Goldman & Bennett (Editors), W.B. Saunders Company (Publisher). Chapter 198, pp. 1060-1074.
Ukrainets, I. V. et al., “Effective Synthesis of 3-(Benzimidazol-2-yl)-4-Hydroxy-2-Oxo-1,2-Dihydroquinolines,”Tetrahedron Letters, vol. 36, No. 42, pp. 7747-7748, 1995; published by Elsevier Science Ltd. (Pergamon).
Heise, C. et al., “In vivo Preclinical Evaluation of Tyrosine Kinase Inhibitors with Potent Effects on Tumor Angiogenesis, Growth and Metastasis,” Abstract and material for a presentation at the American Association for Cancer Research meeting held in Apr. 2002.
Beebe, J. S. et al., “Pharmacological Characterization of CP-547,632, a Novel Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor forCancer Therapy,” Cancer Research, vol. 63, pp. 7301-7309, Nov. 2003;.
Lee, S. H. et al., “In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models,”Clin. Cancer Res., vol. 11, No. 10, pp. 3633-3641, May 15, 2005.
Lopes de Menezes, D. E. et al., “CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia,”Clin. Cancer Res., vol. 11, No. 14, pp. 5281-5291, Jul. 15, 2005.
Trudel, S. et al., “CHIR-258, a novel multitargeted tyrosine kinase inhibitor for the potential treatment of t(f;14) multiple myeloma,”Blood, vol. 105, No. 7, Apr. 1, 2005; published by The American Society of Hematology.
Wedge, S. R. et al., “ZD6474 Inhibits Vascular Endothelial Growth Factor Signaling, Angiogenesis, and Tumor Growth following Oral Administration,”Cancer Research, vol. 62, pp. 4645-4655, Aug. 1
Jazan Elisa
Machajewski Timothy D.
McBride Christopher
McCrea William R.
Pecchi Sabina
Foley & Lardner LLP
Novartis Vaccines & Diagnostics, Inc.
Seaman D. Margaret
LandOfFree
Quinolinone derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinolinone derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinolinone derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4061317